IRGQ

Summary

IRGQ (immunity related GTPase Q, HGNC:24868) is a protein-coding gene on chromosome 19q13.31, encoding Immunity-related GTPase family Q protein (Q8WZA9). Autophagy receptor that specifically promotes clearance of misfolded MHC class I molecules by targeting them to the lysosome for degradation.

Enables protein-macromolecule adaptor activity. Involved in positive regulation of autophagy; protein quality control for misfolded or incompletely synthesized proteins; and substrate localization to autophagosome. Is active in autophagosome and lysosome.

Source: NCBI Gene 126298 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 80 total
• MANE Select transcript: NM_001007561

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24868
Approved symbol	IRGQ
Name	immunity related GTPase Q
Location	19q13.31
Locus type	gene with protein product
Status	Approved
Aliases	FKSG27
Ensembl gene	ENSG00000167378
Ensembl biotype	protein_coding
OMIM	621081
Entrez	126298

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000422989, ENST00000601520, ENST00000602269, ENST00000939533, ENST00000972065

RefSeq mRNA: 2 — MANE Select: NM_001007561 NM_001007561, NM_001388309

CCDS: CCDS33040

Canonical transcript exons

ENST00000422989 — 3 exons

Exon	Start	End
ENSE00001630906	43584367	43593367
ENSE00001704074	43594809	43595340
ENSE00003920726	43595982	43596134

Expression profiles

Bgee: expression breadth ubiquitous, 282 present calls, max score 93.84.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.3870 / max 188.2359, expressed in 1783 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
181291	4.4313	1647
181294	2.1176	1011
181293	1.7981	923
181292	1.0400	680

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
type B pancreatic cell	CL:0000169	93.84	silver quality
olfactory bulb	UBERON:0002264	93.55	gold quality
cortical plate	UBERON:0005343	91.93	gold quality
lateral nuclear group of thalamus	UBERON:0002736	91.73	gold quality
gluteal muscle	UBERON:0002000	91.72	silver quality
substantia nigra pars compacta	UBERON:0001965	91.10	gold quality
vena cava	UBERON:0004087	90.06	gold quality
substantia nigra pars reticulata	UBERON:0001966	89.27	gold quality
ganglionic eminence	UBERON:0004023	89.16	gold quality
dorsal root ganglion	UBERON:0000044	88.77	gold quality
Brodmann (1909) area 46	UBERON:0006483	88.58	gold quality
right hemisphere of cerebellum	UBERON:0014890	88.56	gold quality
embryo	UBERON:0000922	88.51	gold quality
lateral globus pallidus	UBERON:0002476	88.39	gold quality
dorsal plus ventral thalamus	UBERON:0001897	88.32	gold quality
cerebellar hemisphere	UBERON:0002245	88.18	gold quality
superior vestibular nucleus	UBERON:0007227	88.13	gold quality
cerebellum	UBERON:0002037	88.08	gold quality
cerebellar cortex	UBERON:0002129	88.07	gold quality
triceps brachii	UBERON:0001509	87.97	silver quality
right frontal lobe	UBERON:0002810	87.83	gold quality
pons	UBERON:0000988	87.33	gold quality
body of tongue	UBERON:0011876	87.07	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	87.00	gold quality
adenohypophysis	UBERON:0002196	86.82	gold quality
middle temporal gyrus	UBERON:0002771	86.71	gold quality
ventral tegmental area	UBERON:0002691	86.62	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	86.49	gold quality
trachea	UBERON:0003126	86.41	gold quality
synovial joint	UBERON:0002217	86.32	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.66
E-MTAB-6075	no	581.75

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

281 targeting IRGQ, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-6499-3P	99.90	66.38	1212

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Irgq	ENSMUSG00000041037
rattus_norvegicus	Irgq	ENSRNOG00000070901

Protein

Protein identifiers

Immunity-related GTPase family Q protein — Q8WZA9 (reviewed: Q8WZA9)

All UniProt accessions (1): Q8WZA9

UniProt curated annotations — full annotation on UniProt →

Function. Autophagy receptor that specifically promotes clearance of misfolded MHC class I molecules by targeting them to the lysosome for degradation. Acts as a molecular adapter that specifically recognizes and binds (1) misfolded MHC class I molecules following their ubiquitination, as well as (2) autophagy-related proteins, promoting the recruitment of misfolded MHC class I molecules to autophagy machinery for degradation. Degradation of misfolded MHC class I molecules is essential to prevent accumulation of defective MHC class I complexes at the surface of CD8(+) T-cells and prevent a stronger T-cell-mediated response. In contrast to other members of the family, does not show GTPase activity.

Subunit / interactions. Interacts (via LIR motif 1) with GABARAPL2. Interacts (via LIR motif 2) with MAP1LC3B/LC3B.

Subcellular location. Lysosome. Cytoplasmic vesicle. Autophagosome.

Domain organisation. The LIR motifs (LC3-interacting region) are required for the interaction with ATG8 family proteins GABARAPL2 and MAP1LC3B/LC3B.

Induction. Not induced by interferons.

Similarity. Belongs to the TRAFAC class dynamin-like GTPase superfamily. IRG family.

RefSeq proteins (2): NP_001007562, NP_001375238 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR030385	G_IRG_dom	Domain
IPR040070	IRGQ	Family

UniProt features (25 total): helix 7, strand 6, turn 2, short sequence motif 2, chain 1, domain 1, region of interest 1, coiled-coil region 1, compositionally biased region 1, modified residue 1, disulfide bond 1, mutagenesis site 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
8Q7K	X-RAY DIFFRACTION	1.6
8Q6Q	X-RAY DIFFRACTION	1.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WZA9-F1	67.76	0.12

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 203

Disulfide bonds (1): 152–158

Mutagenesis-validated functional residues (1):

Position	Phenotype
74	abolished interaction with gabarapl2.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 180 (showing top): GOBP_REGULATION_OF_AUTOPHAGY, GOBP_VACUOLE_ORGANIZATION, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_MACROAUTOPHAGY, WANG_LMO4_TARGETS_DN, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS, GOBP_ORGANELLE_ASSEMBLY, GOBP_POSITIVE_REGULATION_OF_AUTOPHAGY, GOBP_PROTEIN_CATABOLIC_PROCESS, GOBP_AUTOPHAGOSOME_ORGANIZATION, GOCC_AUTOPHAGOSOME, GOBP_PROTEOLYSIS, GOMF_GTPASE_ACTIVITY, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES

GO Biological Process (4): protein quality control for misfolded or incompletely synthesized proteins (GO:0006515), positive regulation of autophagy (GO:0010508), substrate localization to autophagosome (GO:0061753), autophagy (GO:0006914)

GO Molecular Function (3): protein-macromolecule adaptor activity (GO:0030674), protein binding (GO:0005515), GTP binding (GO:0005525)

GO Cellular Component (3): lysosome (GO:0005764), autophagosome (GO:0005776), cytoplasmic vesicle (GO:0031410)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein catabolic process	1
autophagy	1
positive regulation of catabolic process	1
regulation of autophagy	1
autophagosome assembly	1
establishment of localization in cell	1
catabolic process	1
transmembrane transport	1
process utilizing autophagic mechanism	1
protein binding	1
molecular adaptor activity	1
binding	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
lytic vacuole	1
vacuole	1
cytoplasm	1
intracellular vesicle	1

Protein interactions and networks

STRING

1203 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IRGQ	REPS1	Q96D71	562
IRGQ	TTC9B	Q8N6N2	558
IRGQ	AATF	Q9NY61	549
IRGQ	DMAC2	Q9NW81	520
IRGQ	CPNE1	Q99829	505
IRGQ	ABRACL	Q9P1F3	494
IRGQ	TULP2	O00295	486
IRGQ	LRFN3	Q9BTN0	471
IRGQ	ADPGK	Q9BRR6	462
IRGQ	OR10S1	Q8NGN2	444
IRGQ	SBK1	Q52WX2	433
IRGQ	N4BP2L2	Q92802	431
IRGQ	CORO6	Q6QEF8	424
IRGQ	ZIK1	Q3SY52	411
IRGQ	IRGM	A1A4Y4	405

IntAct

43 interactions, top by confidence:

A	B	Type	Score
GABARAPL2	IPO5	psi-mi:“MI:0914”(association)	0.690
IRGQ	MAP1LC3A	psi-mi:“MI:0915”(physical association)	0.660
IRGQ	MAP1LC3B	psi-mi:“MI:0915”(physical association)	0.660
TGIF2LY	PGP	psi-mi:“MI:0914”(association)	0.640
OR5F1	UBA6	psi-mi:“MI:0914”(association)	0.530
OR10H3	HMGCS1	psi-mi:“MI:0914”(association)	0.530
NPC2	NME2P1	psi-mi:“MI:0914”(association)	0.530
Cdk1	IFT88	psi-mi:“MI:0914”(association)	0.350
Eea1	WWP2	psi-mi:“MI:0914”(association)	0.350
Setd3	PACSIN1	psi-mi:“MI:0914”(association)	0.350
ZSCAN26	TDG	psi-mi:“MI:0914”(association)	0.350
Tmed10	NDUFS8	psi-mi:“MI:0914”(association)	0.350
PLK2	C1orf226	psi-mi:“MI:0914”(association)	0.350
PRNP	CARNS1	psi-mi:“MI:0914”(association)	0.350
SLC25A32	NEDD8-MDP1	psi-mi:“MI:0914”(association)	0.350
NPC2	NME2	psi-mi:“MI:0914”(association)	0.350
NFYA	NME2P1	psi-mi:“MI:0914”(association)	0.350
SCG3	TPM2	psi-mi:“MI:0914”(association)	0.350
GABARAPL2		psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
MED13L	IGKV1-8	psi-mi:“MI:0914”(association)	0.350
SLC25A32	AKR1A1	psi-mi:“MI:0914”(association)	0.350
SCG3	CTH	psi-mi:“MI:0914”(association)	0.350
MRPL49	UBA6	psi-mi:“MI:0914”(association)	0.350

BioGRID (41): IRGQ (Affinity Capture-MS), IRGQ (Co-fractionation), IRGQ (Affinity Capture-MS), IRGQ (Affinity Capture-MS), IRGQ (Affinity Capture-MS), IRGQ (Affinity Capture-MS), IRGQ (Affinity Capture-MS), IRGQ (Affinity Capture-MS), IRGQ (Affinity Capture-MS), IRGQ (Affinity Capture-MS), IRGQ (Affinity Capture-MS), IRGQ (Affinity Capture-MS), IRGQ (Affinity Capture-MS), IRGQ (Affinity Capture-MS), IRGQ (Affinity Capture-MS)

ESM2 similar proteins: A0A061IR73, A6H687, A6NKF1, D3KCC4, E1BD59, G3MY25, G3MZC5, O00634, O75064, P0C5W1, P20863, P27539, P52824, P54777, Q002B5, Q08DM2, Q0VCE3, Q13608, Q17RN3, Q2TBW5, Q3U0S6, Q4VYA0, Q53EQ6, Q561R2, Q568Y2, Q5BK61, Q5JR98, Q5RE82, Q5U651, Q6F5E8, Q6NY19, Q6ZS72, Q8BH83, Q8C052, Q8CDY7, Q8VIM9, Q8WZA9, Q90343, Q90ZN1, Q92985

Diamond homologs: Q8C262, Q8VIM9, Q8WZA9, Q32KW9, Q6AYF9, Q6NXR0

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 49 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Macroautophagy	6	21.0×	5e-05

GO biological processes:

GO term	Partners	Fold	FDR
mitophagy	7	57.1×	4e-09
autophagosome maturation	6	54.0×	1e-07
autophagosome assembly	6	34.6×	1e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

80 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	77
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

675 predictions. Top by Δscore:

Variant	Effect	Δscore
19:43593368:C:CC	acceptor_gain	1.0000
19:43594806:CA:C	donor_loss	1.0000
19:43594807:A:AC	donor_gain	1.0000
19:43594807:ACCT:A	donor_gain	1.0000
19:43594808:C:CA	donor_gain	1.0000
19:43594808:CCT:C	donor_gain	1.0000
19:43594808:CCTC:C	donor_gain	1.0000
19:43592846:C:CA	donor_gain	0.9900
19:43593363:GGAGC:G	acceptor_gain	0.9900
19:43593364:GAGC:G	acceptor_gain	0.9900
19:43593366:GC:G	acceptor_gain	0.9900
19:43593367:CC:C	acceptor_gain	0.9900
19:43593368:C:G	acceptor_loss	0.9900
19:43593369:T:A	acceptor_loss	0.9900
19:43594807:AC:A	donor_gain	0.9900
19:43594807:ACCTC:A	donor_gain	0.9900
19:43594808:CC:C	donor_gain	0.9900
19:43594808:CCTCC:C	donor_gain	0.9900
19:43595336:CATGG:C	acceptor_gain	0.9900
19:43595338:TGG:T	acceptor_gain	0.9900
19:43595339:GG:G	acceptor_gain	0.9900
19:43595341:C:CC	acceptor_gain	0.9900
19:43596000:A:AC	donor_gain	0.9900
19:43596001:C:CC	donor_gain	0.9900
19:43592028:A:AC	donor_gain	0.9800
19:43592029:C:CC	donor_gain	0.9800
19:43592845:G:A	donor_gain	0.9800
19:43593365:AGC:A	acceptor_gain	0.9800
19:43595337:ATGG:A	acceptor_gain	0.9800
19:43595350:A:T	acceptor_gain	0.9800

AlphaMissense

3861 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:43592431:A:C	S489R	0.994
19:43592431:A:T	S489R	0.994
19:43592433:T:G	S489R	0.994
19:43593340:G:C	F186L	0.993
19:43593340:G:T	F186L	0.993
19:43593342:A:G	F186L	0.993
19:43595304:A:G	F12S	0.991
19:43592384:T:A	D505V	0.989
19:43592479:C:A	K473N	0.989
19:43592479:C:G	K473N	0.989
19:43592088:C:G	A604P	0.988
19:43595299:C:G	G14R	0.987
19:43595299:C:T	G14R	0.987
19:43592352:A:G	W516R	0.985
19:43592352:A:T	W516R	0.985
19:43592385:C:A	D505Y	0.985
19:43593300:C:G	A200P	0.984
19:43592108:G:T	A597D	0.983
19:43592454:A:G	W482R	0.982
19:43592454:A:T	W482R	0.982
19:43592118:A:C	Y594D	0.981
19:43592350:C:A	W516C	0.981
19:43592350:C:G	W516C	0.981
19:43592452:C:A	W482C	0.981
19:43592452:C:G	W482C	0.981
19:43593295:A:C	F201L	0.981
19:43593295:A:T	F201L	0.981
19:43593297:A:G	F201L	0.981
19:43595298:C:T	G14E	0.981
19:43595299:C:A	G14W	0.981

dbSNP variants (sampled 300 via entrez): RS1000006746 (19:43584563 G>C,T), RS1000301047 (19:43596524 T>G), RS1000781750 (19:43590421 C>A,T), RS1000828208 (19:43589166 G>A), RS1000880594 (19:43588760 G>A), RS1001605966 (19:43598033 A>G), RS1001621137 (19:43591024 C>T), RS1001622941 (19:43585852 A>G), RS1002103279 (19:43584804 C>G), RS1002790807 (19:43587527 C>T), RS1003214149 (19:43593691 G>A,T), RS1003237571 (19:43585613 C>T), RS1003295581 (19:43587304 T>C), RS1004008856 (19:43586615 A>G), RS1004117278 (19:43593247 C>T)

Disease associations

OMIM: gene MIM:621081 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation, affects expression	3
Air Pollutants	affects cotreatment, decreases expression, increases abundance, affects expression	2
Lead	affects expression, decreases expression	2
Ozone	affects expression, affects cotreatment, decreases expression, increases abundance	2
aristolochic acid I	increases expression	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
bisphenol A	increases expression	1
dimethylselenide	increases expression, increases oxidation	1
sodium arsenite	increases expression	1
methacrylaldehyde	increases abundance, affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
nutlin 3	affects cotreatment, increases secretion	1
torcetrapib	increases expression	1
jinfukang	affects cotreatment, increases expression	1
LDN 193189	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Arsenicals	decreases expression	1
Cisplatin	affects cotreatment, increases expression	1
Dactinomycin	affects cotreatment, increases secretion	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	increases O-linked glycosylation, decreases activity	1
Ivermectin	decreases expression	1
Urethane	increases expression	1
Reactive Oxygen Species	increases expression, increases oxidation	1
Cadmium Chloride	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer